# Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children

> **NCT05854511** · PHASE3 · UNKNOWN · sponsor: **Ain Shams University** · enrollment: 30 (estimated)

## Conditions studied

- HCV

## Interventions

- **DRUG:** Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets

## Key facts

- **NCT ID:** NCT05854511
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-05
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-04-13
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05854511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05854511, "Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05854511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*